Clinical Scorecard: Atsena Reports LIGHTHOUSE data at ARVO
At a Glance
| Category | Detail |
|---|---|
| Condition | X-linked retinoschisis (XLRS) |
| Key Mechanisms | Gene therapy using ATSN-201 with AAV.SPR capsid for targeted gene expression in photoreceptors. |
| Target Population | Male patients ages 6 and older with XLRS caused by RS1 gene mutations. |
| Care Setting | Clinical trial setting, specifically a phase 1/2 study. |
Key Highlights
- ATSN-201 shows good safety and efficacy signs in Part A of the LIGHTHOUSE study.
- No serious adverse events related to treatment reported; most adverse events were Grade 1-2.
- Enrollment for Part B is ongoing, evaluating additional adult and pediatric patients.
Guideline-Based Recommendations
Diagnosis
- Clinical diagnosis of XLRS based on RS1 gene mutations.
Management
- Subretinal injection of ATSN-201 in a dose-escalation and dose-expansion trial.
Monitoring & Follow-up
- Assessment of safety and efficacy through microperimetry, visual acuity, and macular structure.
Risks
- Surgical risks related to the procedure; no dose-limiting toxicities observed.
Patient & Prescribing Data
Adult and pediatric patients with XLRS.
ATSN-201 was well tolerated with no treatment-related serious adverse events.
Clinical Best Practices
- Monitor patients for adverse events related to the surgical procedure.
- Evaluate preliminary data from adult cohort before dosing pediatric patients.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.